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Ovarian epithelial cancer is the most lethal gynecologic malignancy. The high mortality is attributed to the fact that most
cases typically present in late stage when ovarian cancer (OC) has already spread beyond the ovary. Ovarian epithelial cancer
cells are shed into intraperitoneal ascites and easily disseminate throughout the peritoneal cavity with preferential metastasis
to the omentum, peritoneum, and local organs. Understanding how ovarian epithelial cells interact with and modulate their
microenvironment can provide insight into the molecular mechanism(s) involved with malignant transformation and progression
which may eventually identify novel diagnostic, prognostic, and therapeutic targets. The objective of this paper is to provide a brief
consideration of ovarian surface epithelial-stromal interactions in regard to normal physiological function and tumor progression
as inﬂuenced by two potentially key interleukins, interleukins-1 (IL-1) and -6 (IL-6), present in the microenvironment. Lastly, we
will consider the clinical implications of IL-1 and IL-6 for OC patients.
1.Introduction
Ovarian cancer (OC) is the leading cause of gynecologic
cancer death in women in the US. It is the fourth leading
cause of cancer death among women after lung, breast, and
colorectal cancer and is associated with a 1.7% lifetime risk
[1–4]. It is estimated that 23,100 new cases are diagnosed
in the US annually [4] and that 14,000 women die annually
fromthisdisease.Theone-yearsurvivalrateforOCcanbeas
high as 79% and when diagnosed in an early stage the 5-year
survival rate is almost 95% [4]. However, when diagnosed
at a later stage, the 5-year survival is generally no better
than 35% [4]. Optimal cytoreduction followed by platinum-
based chemotherapy remains the mainstay of therapy in
the management of advanced epithelial ovarian cancers [2].
However, while the response rate to primary chemotherapy
c a nb ea sh i g ha s7 6 % ,r e s p o n s er a t ei sd r a m a t i c a l l yr e d u c e d
after relapse of disease [5]. Platinum resistance, deﬁned as
disease recurrence less than six months from completion of
therapy, is an important prognostic predictor. Patients with
platinum-resistant tumors have a response rate of less than
10% when retreated with platinum compounds [6, 7]a n d
alternative options also have poor response rates of 18–30%
[8–15].
Ovarian surface epithelium-(OSE-) derived tumors ac-
count for 90% of malignant ovarian tumors with serous
tumors accounting for over 30% of all OSE-derived cancers
[16]. The majority of ovarian cancers are sporadic in origin,
but about 10% of all epithelial ovarian carcinomas are asso-
ciated with a hereditary predisposition and are characterized
by an increased incidence and earlier onset of disease [17].
Epidemiological studies suggest that besides race [18]a n d
familial history of breast or ovarian cancer [19–21], events
associated with OSE traumatization may result in aberrant
OSEgrowthleadingtoovarianepithelialcarcinogenesis[22].
Thus, increased age, reproductive history (nulliparity), early
menarche, late menopause, and fertility drug use increase
the risk for OC. In contrast, suppression of ovulation by
pregnancy, lactation, or oral contraceptive use decrease the
risk for OC. Lifestyle factors including dietary fat intake and2 Obstetrics and Gynecology International
smoking may also increase the risk for OC while dietary
intake of vitamins A, C, D, and E may protect against OC
[23–25].
The high mortality associated with this disease is gener-
ally attributed to the fact that most cases typically present
in late stage when OC has already spread beyond the ovary,
thatthediseaseisgenerallyasymptomaticinearlystages,and
that an eﬀective screening test is lacking [25, 26]. In addition
to involving the ovary, ovarian epithelial cancer cells are
shed into intraperitoneal ascites ﬂuid and easily disseminate
throughout the peritoneal cavity with preferential mestasta-
sis to the omentum and peritoneum as well as other local
organs.
The etiology of OC is not completely known and can
be attributed to genetic instability associated with repeated
repair of ovulatory defects, elevated gonadotropin levels
with inclusion cysts, or explantation of Fallopian tube
material. Understanding how ovarian epithelial cells interact
with and modulate their microenvironment contributing
to cancer initiation and progression can provide insight
intomolecularmechanism(s)involvedwithmalignanttrans-
formation which may eventually identify novel diagnostic,
prognostic, and therapeutic targets. Interleukin-1 (IL-1) and
interleukin-6 (IL-6) may prove to be such targets. Both
cytokines contribute to the progression of OC by promoting
angiogenesis, metastasis, and chemoresistance. The main
focus of this paper, then, will be to brieﬂy describe the role
of IL-6 in OC progression and to more thoroughly examine
the role of the lesser understood IL-1 in relation to OC
progression and its capacity as a possible therapeutic target.
This paper was conducted using a broad literature survey
encompassing the past 25 years of basic and clinical research
publications exploring IL-1 and IL-6 as each pertains to
ovarian cancer prognosis, progression, and treatment.
2.OvarianSurfaceEpithelium:Extracellular
Matrix Interactions
Despite the fact that over 85% of ovarian cancers arise from
and/orinvolvetheOSE[2,50],thereasonsforthepropensity
of OC development are still poorly understood. However,
due to the common embryonic origin of OSE with the
epithelia lining Fallopian tube, endometrium, and cervix,
histologic subtypes of OSE-derived tumors include serous,
endometrioid, and mucinous tumors, respectively. Likewise,
the expression of stromal characteristics by OSE cells may be
related to their shared mesodermal origin from the coelomic
epithelium and to their close developmental relationship to
ovarian stromal ﬁbroblasts. For example, OSE express both
vimentin and keratin intermediate ﬁlaments characteristic
of connective tissue and epithelium, respectively [51]. Fur-
ther, when maintained on collagen type I gel, OSE cells
undergo a modulation into a spindle-like morphology which
accompanies collagen gel contraction [52]. In contrast,
OSE cells invade Matrigel and can remodel extracellular
matrix (ECM) by secretion of collagenase, gelatinase and
stromelysin as well as produce laminin and collagens I, III
and IV [53, 54]. Consequently, the interaction with stroma
and the ability of OSE to produce, lyse, and reconstruct ECM
indicates that OSE has the capacity to undergo epithelial-
mesenchymal conversions which may not only be necessary
for restoring the integrity of the OSE following ovulatory
damage, but may also contribute to invasion and metastasis
with malignant transformation of the OSE.
3.OvarianCancer and
Epithelial-Mesenchymal Transition
Epithelial-mesenchymal transition (EMT) is characterized
by the disruption of cellular junctions and loss of cellular
polarity resulting in morphologic modulation into a ﬁbrob-
lastic phenotype accompanied by increased cell motility
and invasion [55]. Embryonically, EMT contributes to gas-
trulation, and in the ovary to gonadal development [56].
During tissue repair following ovulation, OSE undergoes
EMT in response to its local microenvironment into a ﬁ-
broblast-like phenotype which promotes OSE migration,
proliferation, and matrix remodeling to repair the ovulatory
defect. “Incessant ovulation” proposes that repeated injury
to the OSE with subsequent rounds of cellular proliferation
cannot only lead to the acquisition of replicative DNA
errors contributing to genetic instability and ensuing malig-
nant transformation [57], but also to chronic inﬂamma-
tion [58]. Such inﬂammation is associated with oxidative
stress and recruitment of activated immune cells, including
macrophages, T cells, B cells, natural killer cells, neutrophils,
and granulocytes [59] resulting in a locally marked increase
in cytokines/chemokines (interleukins and tumor necro-
sis factors) and matrix-remodeling enzymes (plasminogen
activators and collagenases) that can also promote tumor
formation [57].
EMT and subsequent mesenchymal-epithelial (MET)
transitions associated with alterations of E-cadherin expres-
sion [60] are among the most dramatic examples of OSE
plasticity in response to its microenvironment and rep-
resent critical steps in ovarian tumor progression. Owing
to the mesodermal origin of OSE, normal OSE express
N-cadherin, but not E-cadherin. However, in contrast to
loss of E-cadherin expression with tumor progression in
most epithelial cancers, E-cadherin is often reexpressed in
OSE lining crypts and inclusion cysts as well as in benign,
borderline, and primary ovarian cancers [60]. Importantly,
given that OC metastasizes by shedding into the peritoneal
cavity as single cells or cell clusters, transient E-cadherin re-
expression maintains OC aggregate formation and survival
in the peritoneal cavity [61]. OC aggregates, mesothelial
cells, and surrounding blood cells all secrete cytokines that
support OC survival in ascites so that both autocrine and
paracrine mechanisms sustain OC EMT in ascites ﬂuid and
promote establishment of metastatic disease. The reverse
process of MET results from loss of transient E-cadherin
expression so that established metastasticovarian cancers are
frequently devoid of E-cadherin [62]. Pathways promoting
EMT in OSE rely on complex interactions between OSE and
its extracellular components and consist of autocrine andObstetrics and Gynecology International 3
paracrine interactions with hormones and cytokines includ-
ing transforming growth factor-β [63], epidermal growth
factor[64],hepatocytegrowthfactor[65],endothelin-1[66],
and bone morphogenic protein 4 (BMP4) [67]. Interestingly,
e p i d e r m a lg r o w t hf a c t o r / e p i d e r m a lg r o w t hf a c t o rr e c e p t o r
signaling induces EMT in cultures of OC cell lines and is also
associated with enhanced expression and secretion of IL-6,
resulting in increased cellular motility [68].
In addition to promoting a migratory and invasive
phenotype,EMTmaycontributetopatientmortalitybycon-
ferring paclitaxel resistance in epithelial ovarian cancer cells
[69], inducing myocyte diﬀerentiation into CD14+/KDR+
proangiogenic cells thereby promoting tumor angiogenesis
and vascularization [70], and inducing the diﬀerentiation
of stromal mesenchymal stem cells into tumor associated
ﬁbroblasts that support disease progression through matrix
remodeling [41]. In this last context, it is interesting that
both in vivo and in vitro studies indicate that IL-6 produced
by stromal tumor associated ﬁbroblasts also enhances OC
cell proliferation through activated signal transducer and
activator of transcription 3 (STAT3) signaling [41].
While nonsteroidal anti-inﬂammatory drugs (NSAIDS)
have failed to protect against development of OC [71, 72],
inﬂammation may still contribute to the clinical develop-
ment of OC. In addition to presenting as an inﬂammatory
disease, inﬂammation of the ovarian epithelium has been
associated with increased risk for OC [58, 73–75]a n d
endometriosis is associated risk for clear cell carcinoma of
the ovary [71, 76–79]. Consequently, the potential clinical
contribution of inﬂammatory mediators, IL-6 and IL-1, for
ovarian tumor initiation and progression should not be
overlooked.
4.Interleukin-6
IL-6 is a pleiotropic cytokine that plays a major role in
the immune system in response to injury and infection,
as well as, inﬂammation [45]. IL-6 is produced by T cells,
monocytes, ﬁbroblasts, endothelial cells, and keratinocytes
[80]. Depending on the experimental system, IL-6 has
been suggested to have both proinﬂammatory and anti-
inﬂammatory properties in vitro and in vivo [81]. How-
ever, it appears that IL-6 acts predominately as an anti-
inﬂammatory and immunosuppressive cytokine by directly
suppressing IL-1 and tumor necrosis factor-α (TNF-α),
inducing release of glucocorticoids, and inducing natural
antagonists to IL-1 and TNF-α [81]. In an in vitro prostate
cancer model, cancer-associated ﬁbroblasts secreted higher
amounts of IL-6 than normal ﬁbroblasts which resulted
in an increased proliferation of normal epithelial cells and
increased endothelial cell migration towards the cancer-
associated ﬁbroblasts and/or their conditioned media [82].
It is not surprising then that Spaeth et al. [41] found that
tumor-associated ﬁbroblasts derived and diﬀerentiated from
mesenchymal stromal stem cells produced and secreted IL-6
that similarly promoted OC cell proliferation [41].
In the normal ovary, aside from production by activated
stromal immune cells, IL-6 is produced by granulosa cells
[83]andOSEcells[84,85].However,neoplasticovariancells
also routinely overexpress IL-6 in vitro [84–86]a n dg r e a t e r
amounts of IL-6 are present in the cystic ﬂuid of malignant
tumors when compared to cystic ﬂuid of benign tumors
[80]. Likewise, OC ascites are rich in IL-6 [46, 87–89].
Consequently, elevated levels of IL-6 in the blood and ascites
are associated with poor prognosis in OC [90]. Interestingly,
elevated serum IL-6 levels are uniquely associated with OC
compared to other gynecological malignancies and although
this is a much less sensitive biomarker for OC than CA125
[46], it may still serve as a useful prognostic indicator of
disease.
While the role of IL-6 in the etiology of OC is not fully
understood, we might predict that IL-6 contributes to OC
by promoting angiogenesis, tumor invasion, and chemore-
sistance. Speciﬁcally, in vivo treatment with IL-6-induced
angiogenesis and enhanced endothelial cell-mediated migra-
tion of human ovarian carcinoma cells [42]. IL-6 may also
be involved in the tumorigenic processes of OC cell lines by
increasingtheircapacitytosecretematrixmetalloproteinase-
9 (MMP-9) [43]. Further, OC cell lines cultured with IL-
6 demonstrate increased chemotactic and/or chemokinetic
activity and increased overall invasiveness [44]. Overex-
pression of IL-6 is also associated with chemoresistance in
OC cells [46, 47]. In vitro studies of OC cell lines further
show that autocrine production of IL-6 decreased their
responsiveness to cisplatin and paclitaxel [45].
Interestingly both IL-6 and IL-1 levels are elevated in
ascites. In vitro studies show that treatment of granulosa
cellswithIL-1increasesIL-6productioninadose-dependent
manner[83]and,likewise,treatmentofOCcelllineswithIL-
1β,leadtoincreasedsecretionofIL-6[91].Consequently,the
contribution of IL-1 to initiate and promote OC progression
by regulating IL-6 expression deserves consideration.
5.Interleukin-1
There are 11 members of the IL-1 cytokine family that have
proinﬂammatory or anti-inﬂammatory activity. The most
thoroughly studied cytokines from this family are two ago-
nist cytokines: IL-1α and IL-1β and one antagonist cytokine:
interleukin-1 receptor antagonist (IL-1Ra). Though all of
these cytokines are associated with chronic inﬂammatory
diseases (CIDs), IL-1β appears to be the primary mediator
of inﬂammation in CIDs [39].
IL-1β is synthesized in a precursor form as a 31kD
protein that is cleaved by caspase-1 into its active 17kD
mature secreted form [92]. IL-1β is mainly produced by
monocytes and macrophages, but can also be produced by
endothelial cells, ﬁbroblasts, and epidermal cells in response
to bacterial or innate immunity stimulation [93]. Both nor-
mal and malignant epithelial ovarian cells also produce IL-1
[90], although activated immune cells in the stroma remain
the major source of IL-1 [94]. Constitutive production of IL-
1β by ovarian carcinoma cells [95] enhances their invasion
capacities by increasing expression of MMP-1 [36]a n d
stimulating production of proangiogenic factors such as vas-
cular endothelial growth factor (VEGF) [37]. Additionally,4 Obstetrics and Gynecology International
ﬁbroblasts cultured with conditioned media from a highly
metastaticOCcelllineorwithIL-1β inducedtransformation
of the ﬁbroblasts to myoﬁbroblasts expressing α-smooth
muscle actin (α-SMA) [38]. This coincided with induction
of myoﬁbroblast expression of ﬁbroblast activation protein
(FAP),acell-surfaceserineproteasewithcapacitytoremodel
ECMbycleavingcollagentype1[38],therebypromotingOC
cell migration and invasion.
IL-1α is likewise synthesized in a precursor form as a
31kD protein that is cleaved by Ca2+-dependent protease
calpain into an active 17kD mature cell-associated form
[28, 92]. IL-1α is produced by monocytes, macrophages,
epithelial cells, keratinocytes, and ﬁbroblasts [96]. However,
because it remains mainly cell-associated, IL-1α induces less
inﬂammation and angiogenesis than IL-1β [27]. Further,
since IL-1α is generally secreted to a lesser extent than IL-
1β, it is not commonly detected in bodily ﬂuids except when
released from necrotizing cells in cases of severe inﬂamma-
tion [28]. In its cell-associated form, IL-1α m a i n l ya c t sa sa
tumor suppressor in malignant cells by recruiting immuno-
competent cells to the tumor microenvironment and assist-
ing in an immunologic response to combat tumor growth
[28–31]. IL-1α tumor suppressor characteristics have been
further conﬁrmed in vivo where IL-1α produced by tumori-
genic ﬁbroblasts decreased the number of tumor growths, as
well as increased tumor rejection by facilitating activation
and expansion of helper T cells [32, 33]. Consequently, in
OC,IL-1β generallypromotesinvasiveness,tumorangiogen-
esis and induces immune suppression while IL-1α reduces
tumorigenicity by inducing antitumor immunity [97].
Lastly, IL-1Ra is an antagonist that inhibits IL-1α and IL-
1β from binding to both IL-1 receptors, but does not activate
IL-1 receptor cell signaling cascades. IL-1Ra is secreted by
the same cell types as IL-1α and IL-1β including monocytes,
macrophages, and OSE [98]. Further, high levels of IL-1Ra in
cultured tumor-derived macrophages compared to cultured
tumor-derived ovarian epithelial cells [99] suggest that the
major contributors of IL-1Ra are activated macrophages.
IL-1Ra is excessively abundant in the ascites of late-stage
OC patients compared to IL-1Ra levels in ascites and/or
serumlevelsfromearly-stageOCandbenignovariantumors
[40]. Higher levels of IL-1Ra in ascites and/or serum appear
associated with poor prognosis and reduced overall survival
[40]. Since IL-1Ra does not activate IL-1 receptor cell
signaling cascades and IL-1Ra production can be induced
by IL-1β and/or IL-1α, it is plausible that the increased
IL-1Ra in the ascites and the associated poor prognosis is
due to secreted IL-1β signaling [31]. In agreement, Mustea
et al. found that increased levels of IL-1β in the serum
and/or ascites were associated with decreased survival [40].
Therefore, it is imperative to further understand the clinical
signiﬁcance of the IL-1 family in the progression of OC as
well as potential treatment targets.
6.ClinicalRelevance
Phase I and II clinical trials utilizing recombinant human IL-
6 in conjunction with chemotherapy increased OC patient
plateletcountalleviatingthrombocytopenia[48,49],thereby
comprising adjuvant therapeutic beneﬁts of IL-6. As stated
earlier, IL-1 increases production of IL-6 [83, 91]; therefore,
due to this interrelationship, studies investigating the eﬀect
of IL-1 on the development of OC are clinically important.
A better understanding of the IL-1 cytokines’ functions in
relationship to OC may help to identify novel prophylactic
drug treatments and/or treatments after disease occurrence.
As described earlier, IL-1α has tumor suppressor func-
tions that should be further investigated in OC; however,
the eﬀectiveness of IL-1α as a treatment option is likely
limited to early onset of disease. When released in its
precursor form, such as from necrotic tumor cells under
hypoxic conditions commonly seen in OC [96], IL-1α can
promoteaninﬂammatory responseperpetuating thechronic
inﬂammation associated with the onset of disease [96].
Yet, when released in its cleaved form, IL-1α lacks the
ability to interact with its receptor [96] so that treatment
with the precursor form would be expected to elicit a
proinﬂammatory response and treatment with the cleaved
form would elicit no response.
On the other hand, in vitro studies have shown that
IL-1α increases 11β-hydroxysteroid dehydrogenase type 1
(11βHSD1) mRNA expression in human primary OSE [100]
leading to increased rates of cortisone to cortisol conver-
sion by OSE [101] promoting cortisol’s anti-inﬂammatory
potential [102]. However, since 11β-hydroxysteroid dehy-
drogenase type 2 (11βHSD2) activity is greater in OC
tissue compared to normal ovarian tissue [103], it is not
surprising that OC cell lines treated with IL-1α in vitro
induced 11βHSD2 gene expression leading to the reverse
conversion of cortisol to cortisone inactivating the anti-
inﬂammatory actions of 11βHSD1 and, thereby, supporting
tumor cell proliferation [104]. Consequently, the IL-1α-
induced switch from 11βHSD1 to 11βHSD2 associated with
malignant transformation confers a growth advantage to OC
cells [105] and limits the therapeutic potential of IL-1α.
A phase I clinical trial showed recombinant human IL-
1α treatment having minor antitumor eﬀect in advanced
recurrent ovarian cancer [106]. Nonetheless, clinical trials
showed that recombinant human IL-1α treatment acceler-
ated platelet recovery during chemotherapy and reduced
carboplatin-induced thrombocytopenia in patients with
recurrent OC [34], as well as in patients with ovarian
and other cancer types (gastrointestinal, breast, melanoma,
lung, head and neck, sarcoma, and prostate) who did not
receive concomitant chemotherapy [35]. However, IL-6 is
an eﬀective hematopoietic growth factor and plays a direct
role in megakaryocyte diﬀerentiation into platelets [48].
Therefore, it can be hypothesized that the platelet increase
seen in response to recombinant human IL-1α treatment
could also be due to IL-1-induced production of IL-6
[35]. Therefore, more clinical trials should be completed
to test the eﬃciency of IL-1 and/or IL-6 to ameliorate
thrombocytopenia.
In contrast, due to IL-1β’s cancer-promoting activities,
inhibiting IL-1β function represents a promising new avenue
for therapeutic intervention. Developing novel IL-1β antag-
onists that block IL-1β’s ability to bind to its receptor should
suppress IL-1β’s VEGF-mediated angiogenesis, invasiveness,Obstetrics and Gynecology International 5
Table 1: Proposed functions of IL-1 and IL-6 in OC.
Cytokine Inﬂammatory fnction Proposed function in ovarian cancer Model Ref.
IL-1α Proinﬂammatory
(i) Stimulate angiogenesis (i) In vitro/In vivo [27]
(ii) Recruit immunocompetent cells (ii) In vitro/In vivo [28–33]
(iii) Increase platelet count (iii) Phase I clinical trial [34, 35]
IL-1β Proinﬂammatory
(i) Increase expression of MMP-1 (i) In vitro [36]
(ii) Stimulate production of
proangiogenic factors (ii) In vitro [37]
(iii) Promote OC cell migration and
invasion (iii) In vitro [38]
IL-1Ra Anti-inﬂammatory (i) Antagonist to IL-1α and IL-1β [39]
(ii) Abundant in the OC ascites In vivo [31, 40]
IL-6 Anti-inﬂammatory
(i) Promote OC cell proliferation (i) In vitro [41]
(ii) Stimulate angiogenesis (ii) In vitro/In vivo [42]
(iii) Enhance endothelial cell
migration (iii) In vitro/In vivo [42]
(iv) Increase OC cell lines capacity to
secrete MMP-9 (iv) In vitro [43]
(v) Increase chemotactic and/or
chemokinetic activity (v) In vitro [44]
(vi) Increase invasiveness (vi) In vitro [44]
(vii) Induce chemoresistance (vii) In vitro/In vivo [45–47]
(viii) Increase platelet count (viii) Phase I and II clinical trial [48, 49]
and chemoresistance. While published clinical trials of IL-
1β as a therapeutic target in treatment of cancer is limited,
a phase I trial showed treatment with recombinant human
IL-1β elevated platelet levels in patients with gastrointestinal
cancer [107]. However, as stated earlier, IL-1’s ability to
increase platelet levels may be partially due to inducing
production of IL-6. However, due to the aggressiveness of
OC and IL-1β’s promotion of cancer progression, it may
prove more beneﬁcial to evaluate IL-1β as a treatment
target rather than as a therapeutic agent. Therefore, as a
treatment target eﬀective agents would likely mimic the
action of IL-1β’s natural antagonist and/or neutralize IL-1β.
Currently, a recombinant IL-1Ra,Anakinra,which blocks IL-
1β and IL-1α from binding to their receptors, is used for the
treatment of rheumatoid arthritis [108]. Likewise, the fusion
glycoprotein, Rilonacept, which works by binding to IL-1α
and IL-1β with high aﬃnity to neutralize both molecules
is yet another anti-inﬂammatory therapy currently in use
[108]. Lastly, Canakinumab, a fully humanized monoclonal
antibody highly speciﬁc for IL-1β, is currently in clinical
use to suppress inﬂammation [108]. Consequently, these
approved or similarly targeted inﬂammatory medications
may be valuable for their capability to reduce IL-1-induced
disease processes that promote OC.
7. Conclusion
In conclusion, IL-1 and IL-6 signiﬁcantly impact the ovarian
cancerphysiologicandstructuralmicroenvironment.Specif-
ically, either cytokine can promote proliferative, migratory
and invasive changes in ovarian cancer cells. Clinically
recombinant IL-1 and IL-6 may alleviate chemotherapy-
inducedthrombocytopenia.Furthermore,IL-1βneutralizing
treatments, such as those employed in autoinﬂammatory
diseases, combined with chemotherapy may prove beneﬁcial
to reduce IL-1β-mediated angiogenesis and metastasis.
This paper has explored the cancer-promoting aspects
of IL-1 and IL-6 summarized in Table 1, as well as, their
beneﬁcial characteristics in alleviating a chemotherapy side
eﬀect. There is a delicate balance that must be achieved
between using IL-1 and IL-6 for therapeutic purposes,
while also abrogating the cancer-promoting characteristics
of each cytokine. Consequently, further experimental and
clinical studies of IL-1 and IL-6 are warranted and may
provide a better understanding of interleukin-associated
changes to the microenvironment associated with ovarian
cancer progression leading to improved prognosis by novel
treatment options.
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